News

Watch for PET/CT to grow as an aid to image-guided biopsies of children

PET/CT can add value to cancer staging and follow-up in pediatric patients. In fact, it may come to play an important role in directing image-guided biopsies of children, according to a study published in the American Journal of Roentgenology.

Senior author Bairbre Connolly, MD, of the University of Toronto and colleagues note that PET/CT is increasingly used to evaluate adult oncology patients with the radiotracer FDG, which enables precise localization of high cellular activity. But the question has been largely open as to whether FDG PET/CT can be similarly useful in children, who tend to have higher FDG activity in regions of growth, adenoids, tonsils and bone marrow, among other typical FDG differences. Read more.

Experts Call for Expansion of Molecular Imaging in Precision Cancer Care

Penn team says finding a way to use these techniques more widely in clinical settings should be a top priority

New molecular imaging technologies can make it easier to diagnose, monitor, and treat cancers while potentially saving patients from undergoing therapies that are likely to be ineffective and playing a role in minimizing side effects, according to experts from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. In a review published in JAMA Oncology, the Penn team says finding a way to use these techniques more widely in clinical settings should be a top priority.

Precision cancer care focuses on identifying the specific biomarkers of a patient’s cancer, which can help doctors make decisions about the best treatment options. A traditional way to learn about the genetic makeup of cancer is through a biopsy—in which doctors have to physically remove tissue from a patient and then examine it. But new molecular imaging, which can be used to complement the biopsy and is noninvasive, can provide added benefit in certain cases, especially when multiple examinations are needed. Read more.

Patients with psoriasis associated with increased systemic arterial and subcutaneous adipose inflammation

Psoriasis is a chronic, inflammatory skin disorder associated with an increased risk for coronary artery disease, likely resulting from a systemic pro-inflammatory state. In addition, previous studies demonstrate that subcutaneous adipose tissue inflammation, which may contribute to the pathogenesis of psoriasis, is also associated with an increased risk of cardiovascular disease. Given the multiple associations demonstrated between psoriasis, inflammation, and atherosclerotic disease, the objective of this study was to assess the relationship between global vascular inflammation and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Read more.

Imaging glucose uptake inside single cells

Stimulated Raman scattering is used together with a novel, small-alkyne-tagged glucose analogue to visualize glucose uptake activity at the single-cell level.

Almost all living organisms—from bacteria to humans—require glucose as an energy source, i.e., cells constantly take up glucose to satisfy organisms’ energetic needs for survival, maintenance, and proliferation. However, in many diseases (such as obesity, diabetes, and cancer), glucose uptake activity becomes poorly regulated. Visualization of this important process, in both physiological and pathological conditions, is thus highly desired, and is indispensable for understanding energy metabolism and cellular activity. Over the past few decades several prominent techniques have been developed for the visualization of glucose uptake. Read more.

First patient dosed with PyL, a PSMA-targeted PET/CT imaging agent for prostate cancer

Progenics Pharmaceuticals announced that its first patient has been dosed in the company’s phase 2/3 clinical trial of PSMA-Target PET/CT imaging agent, PyL, which it will be evaluating for diagnostic accuracy. Progenics Pharmaceuticals, which develops medicine and other products targeting the treatment of cancer, dosed their first patient at Yale School of Medicine and plans to enroll about 300 patients with high risk prostate cancer with recurrence or metastatic disease in the U.S. and Canada for this part of the study. Read more.

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap